AstraZeneca plc Could Be Back To Growth By 2016

Full-year results could indicate a return to growth sooner than expected for AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When Pascal Soriot took over as the new boss of AstraZeneca (LSE: AZN) (NYSE: AZN.US) in October 2012, his brief was to get the pharmaceuticals giant back to earnings growth as soon as possible.

With patents on a number of key drugs set to expire and the firm’s drugs pipeline looking a little sparse, he had his work cut out for him for sure. But Mr Soriot has surely delighted AstraZeneca shareholders with his whirlwind approach. Lower-margin businesses have been culled, and AstraZeneca has returned to its core strength of developing key new drugs.

FY 2014

Full-year results are due on Thursday 5 February, so what are we likely to see?

At Q3 time the pipeline was looking good, with the company talking of “accelerating its investments in its growth platforms and expanding pipeline“. Guidance for full-year core EPS suggested a drop of 10%, but that was better than previous predictions.

In its outlook for 2015, AstraZeneca also told us it expects core EPS for the year to be “no less than the lower end of the range of the upgraded guidance for Core EPS for 2014 at actual exchange rates“, and that’s possibly the best indication yet that we’re close to a turning point and should soon be seeing a resumption of earnings growth.

Better than expected

AstraZeneca’s recovery so far has been better than anyone really expected back in 2012, and when 2013’s full-year results were released in February 2014 Mr Soriot told us he was “confident that we can return to growth faster than anticipated and expect our 2017 revenues will be broadly in line with 2013“. From that, many observers have been expecting 2017 to be the year that AstraZeneca returns to earnings growth, with cost-cutting and improvements in efficiency turning that revenue growth into a healthier bottom line.

But with every set of results so far, AstraZeneca has done better than expected, and I’m really hoping to see EPS growth a year earlier than that, by 2016. The current consensus suggests EPS falls of 2% in 2015 followed by another 2% in 2016, but forecasts have been gradually creeping upwards in recent months. There’s a 21% fall in reported EPS on the cards for the year just ended, and anything better than that will surely lead to a revision of those forecasts for the next two years.

Worth its premium

AstraZeneca’s forward P/E is a bit higher than average right now, at 18 for 2015 and 18.5 for 2016, but that’s based on an expectation of long-term growth — and there still seems to be a premium left from the aborted Pfizer takeover bid.

But all in all, it’s a very well managed company and it deserves its rating — and we should hear good things next week.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »